Close

Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference Sep 22, 2022 07:30AM
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference Sep 22, 2022 07:30AM
Arbutus Biopharma (ABUS) PT Raised to $6 at Chardan Capital Markets Mar 4, 2022 07:27AM
Arbutus to Participate in October Investor Conferences Sep 28, 2021 07:30AM
Arbutus to Participate in October Investor Conferences Sep 28, 2021 07:30AM


Sep 28, 2020 08:00AM Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
Sep 28, 2020 08:00AM Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
Mar 6, 2020 02:35AM Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Ahead of HBV Clinical Data
Oct 4, 2019 07:44AM Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral
Sep 26, 2019 07:30AM Arbutus to Participate in Upcoming Investor Conferences
Sep 26, 2019 07:30AM Arbutus to Participate in Upcoming Investor Conferences
May 7, 2019 07:00AM Arbutus Biopharma (ABUS) PT Lowered to $5 at Chardan Capital Markets
Oct 9, 2018 08:30AM Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
Oct 9, 2018 08:30AM Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
Oct 2, 2018 08:30AM Arbutus to Present at Chardan’s Genetic Medicines Conference
Oct 2, 2018 08:30AM Arbutus to Present at Chardan’s Genetic Medicines Conference
Mar 19, 2018 07:45AM Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy
Oct 10, 2017 08:00AM Arbutus to Participate in Upcoming Investor Conferences
Apr 4, 2017 09:29AM Pre-Open Movers 04/04: (GNCMA) (PRTK) (CYCC) Higher; (AYI) (KATE) (NVDA) Lower (more...)
Apr 4, 2017 06:00AM Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy
Dec 13, 2016 06:33AM Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral; Safety Risk Overwhelms Promising Efficacy
Nov 30, 2016 06:23AM Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Amid Arrowhead Hepatitis B Program Discontinuations
Oct 14, 2016 07:34AM Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
Jul 8, 2016 10:24AM Notable Analyst Rating Changes 7/8: (CF) (COF) (GFI) Upgraded; (AINV) (HUM) (ABUS) Downgraded
Jul 8, 2016 07:38AM Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Sell
Jun 16, 2016 08:42AM UPDATE: Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
May 16, 2016 11:50AM UPDATE: Notable Analyst Rating Changes 5/16: (NOK) (JCP) (BBT) Upgraded; (DB) (BLOX) (BITA) Downgraded
May 16, 2016 07:33AM Chardan Capital Markets Starts Arbutus Biopharma (ABUS) at Sell